RxDoctor Payments Data

Mehad Musbah, MD

Hospitalist · Washington, DCNPI 1326465204

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 32.1% of the total. Reporting peaked in 2023 at $236 and has fallen 72.4% since, to $65 in 2025. Among hospitalist clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$617in general payments, 2019–2025

Across 31 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$198
  • AbbVie$152
  • Merck$93
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$88
  • Paratek Pharmaceuticals, Inc.$30
  • Smith+Nephew$20
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$617 in reported general payments places this provider in the 90th percentile of 101 hospitalist providers in District of Columbia.

See all hospitalist providers in District of Columbia

Medicare billing

Part B allowed, 2024
$106,792
Medicare patients
393
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium12$53
Furosemide21$40

Paid to pharmacies, not to this prescriber.

Other hospitalist in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →